Benitec Biopharma Inc. Stock 12‑Month Price Target Raised to $24.33, Implies 171% Upside

H.C. Wainwright reiterated a Buy rating and $32 price target for Benitec BioPharma (BNTC) after FDA feedback on BB-301 therapy. The FDA requested additional data, with a final pivotal study design expected in Q1 2027. BNTC stock is down 5.3% weekly and 31% YTD, trading at $9.23. Analysts predict profitability this year, with a consensus high target of $32.

Citizens reiterated a Market Outperform rating and $24.00 price target for Benitec Biopharma (NASDAQ: BNTC), citing constructive FDA feedback on its BB-301 study. The target suggests significant upside from the current $9.23 share price. Benitec plans to finalize the study design with the FDA in Q1 2027 and present updated data at ESGCT. Analysts maintain a Strong Buy consensus, with targets ranging from $17 to $32. The company also appointed Ernst & Young as its new auditor.

Benitec Biopharma (NASDAQ:BNTC) received FDA feedback requesting additional data for its BB-301 pivotal trial, with final design confirmation expected in Q1 2027. Enrollment is planned for mid-2027. The company will present interim clinical results at a congress in October. BB-301 is a genetic medicine candidate for Oculopharyngeal Muscular Dystrophy, with no approved therapies currently available.

Benitec Biopharma (BNTC) reported that its BB-301 pivotal trial remains on track to start mid-2027, following FDA Type C meeting feedback. The FDA requested additional data, including from Benitec's OPMD Natural History Study, to inform the trial's design. The FDA agreed to review submitted data, allowing final pivotal study design confirmation in 1Q 2027. Benitec plans to present 12-month Cohort 1 and interim Cohort 2 BB-301 Phase 1b/2a data at ESGCT in October 2026.

Benitec Biopharma Inc. (BNTC) filed an SEC Form 8-K — Regulation FD Disclosure. Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study • The BB-301 pivotal trial remains on track to begin in mid-2027 • Discussions regarding an open-label, single-arm, pivotal study for BB-301 are ongoing, and based on these di

Benitec Biopharma Inc. (BNTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update • All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all thre